Detail akcie PerkinElmer Inc online

Business Summary: Revvity, Inc. is a provider of health science solutions, technologies, and services, which delivers workflows from discovery to development, and diagnosis to cure. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. It offers instruments, reagents, assay platforms and software to hospitals, and medical labs. It is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Revvity Inc revenues decreased 17% to $2.75B. Net income before extraordinary items decreased 65% to $179.5M. Revenues reflect Diagnostics segment decrease of 28% to $1.46B, Life sciences segment remaining flat at $1.29B, United States segment decrease of 28% to $1.12B, Other Foreign segment decrease of 9% to $1.05B, China segment decrease of 5% to $454.4M.